TNF and uveitis: Adalimumab, a fully humanized IgG1 monoclonal antibody with high affinity for TNF-α, has demonstrated robust efficacy and safety in treating noninfectious uveitis and is widely used in clinical practice [2,3,4,5,6,7,8,9,10,11].